Transaction #30924 · Form 4 · 0001437749-26-032048
Monopar Therapeutics · Exercise / conversion · Common Stock
Monopar Therapeutics · Transacted October 1, 2026 · Filed October 5, 2026
What does this filing report?
An SEC Form 4 filing for Monopar Therapeutics records an exercise / conversion involving Common Stock on October 1, 2026. The reported quantity was 8,400. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Monopar Therapeutics
- Company CIK
- 0001645469
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 8,400
- Reported price
- 0.005
- Reference value
- 42
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 13,573
- Ownership description
- Not reported
- SEC acceptance time
- Oct 5, 2026, 5:43 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- STARR CHRISTOPHER M ↗
Director
CIK 0001235470
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.
- F2
- On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.
- F3
- Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F5
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F6
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.